Company Overview and News

1
CRISPR Therapeutics: Clinical Debut Sets Up Round 1 Of Editing Battle Royale

2018-05-17 seekingalpha
Molecular scissors is a term that is frequently used to describe the cutting molecules of gene editors.

 
Flash - Egypt's president hails 'breakthrough' in Nile dam talks - France 24

2018-05-17 france24
Egyptian President Abdel Fattah al-Sisi said on Wednesday that a "breakthrough" had been reached in talks with Sudan and Ethiopia over a controversial dam the latter is building on the Nile.

3
Bluebird Bio: Gene Therapy Best In Class

2018-05-16 seekingalpha
The current quarterly cash burn remains modest leaving most of the group with enough capital to operate through 3 to 5 years.

 
Bluebird Bio Expands On Partnership To Take A Lead In Immuno-Oncology

2018-05-15 seekingalpha
There is a need for TCRs, because CAR-T are strong but can't target tumor proteins that are inside of cells only those that are expressed on the cell's surface.

2
JF's Core Biotech Buys #14: Introducing Our Final 2 Positions & Taking Advantage Of Weakness In The I-O Space

2018-05-07 seekingalpha
The M&A theme appears set to continue in the spotlight this year, with Gilead to put cash to work and Takeda likely to come to terms with Shire.

 
Celgene (CELG) Q1 Earnings & Sales Beat on Revlimid Strength

2018-05-04 zacks
Celgene Corporation (CELG - Free Report) reported encouraging first-quarter 2018 results wherein both earnings and sales topped expectations.

 
Flash - Nile dam won't harm Egypt, says new Ethiopian leader - France 24

2018-05-04 france24
Ethiopia's newly appointed prime minister, Abiy Ahmed, said on Thursday that the controversial dam his country is building on the Nile will not harm Egypt's share of water supplies.

 
Can Celgene (CELG) Keep Its Earnings Streak Alive in Q1?

2018-05-01 zacks
Celgene Corporation (CELG - Free Report) is scheduled to report first-quarter 2018 results on May 4, before the opening bell.

2
JF's Core Biotech Buys #13: Continued Market Headwinds And How To Respond

2018-05-01 seekingalpha
I remind readers that I am not a market timer, as I have no edge in making predictions.

3
JF's Core Biotech Buys #12: Updates And Introducing Our 18th Selection

2018-04-24 seekingalpha
President Trump´s speech on drug pricing has been postponed. Continued deal activity in the biotech sector bodes well.

 
Bluebird Bio Impresses Yet Again With Gene Therapy Platform

2018-04-23 seekingalpha
Bluebird Bio posts positive phase 1/2 data for its Lentiglobin therapy in beta Thalassemia in the New England Journal Of Medicine Publication.

 
Why Investment Wealth-Builders Disdain Big Pharma Stocks Now

2018-04-20 seekingalpha
This article is a deep-dive learning lesson for those new to or confused by our behavioral analysis of Market-Maker price-range forecasts.

9
JF's Core Biotech Buys #11: Positive News For Several Holdings, A Change To Benchmarks And Introducing Our 17th Position

2018-04-17 seekingalpha
Performance of the Core Biotech Model Account is currently tracking just ahead of the IBB and XBI over the same period of time.

1
Have I Got A Biotech Stock For You

2018-04-17 seekingalpha
I spent a lot of time in Romania during the early 2000's helping companies privatize. There was a ton of opportunity to acquire older, cash-flowing businesses at reasonable valuations. However, most locals weren't so interested in this...instead, the nearly universal comment we got from company owners was, "this company is okay, but let me tell you about this real estate deal I have!"

 
JF's Core Biotech Buys #10: Incyte Disappoints, Optimism Returns To Gene Therapy And A New Position

2018-04-10 seekingalpha
The rollercoaster ride in the gene therapy space (pessimism due to clinical hold/safety fears followed by optimism over Novartis acquiring AveXis) has been an interesting case study to watch.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

20h - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

20h - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...